Author:
Penteado Schmidt Carolina Witchmichen
Publisher
Springer International Publishing
Reference12 articles.
1. Pieters R, Schrappe M, Valsecchi MG, Biondi A, et al. INTERFANT-06: International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia. Stichting Kinderoncologie Nederland. 2016.
https://www.skion.nl/workspace/uploads/Interfant-06_version16b_1aug2016_stop-Rand_MEC.pdf
. Accessed 13 Jan 2017.
2. Interfant 2006. Stichting Kinderoncologie Nederland.
https://www.skion.nl/voor-professionals/behandelrichtlijnen/protocollen/121/interfant-2006
. Accessed 13 Jan 2017.
3. Munõz L, Nomdedéu JF, Villamor N, et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Lekemia. 2003;17:76–82.
4. Grümayer ER, Schmidmeyer W, Panzer S, Gadner H. Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia. Blut. 1986;53(4):309–14.
5. Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–89.